Liver

LONDON — Cirrhosis severity, infections and mortality outcomes were worse for patients in low to middle-income countries, due in part to poor access to liver transplant and ICU facilities, according to data presented here.

LONDON — Ozempic improved cardiometabolic parameters and markers of liver injury yet failed to improve liver fibrosis in patients with nonalcoholic steatohepatitis and compensated cirrhosis, according to late-breaker data presented here.

LONDON — Magnetic resonance elastography in combination with the fibrosis-4 index was a better predictor of significant fibrosis in patients with nonalcoholic fatty liver disease vs. other noninvasive techniques, noted a presenter here.

LONDON — Support vector machines had the highest accuracy in predicting liver decompensation among a subset of patients in Germany compared with other machine learning models, according to data presented at the International Liver Congress.

LONDON — Lower MELD score predicted short- and long-term survival in patients with severe alcohol-associated hepatitis who were declined for early liver transplantation, according to research presented at the International Liver Congress.

LONDON — Patients who received a liver transplant had significantly reduced antibody and T-cell responses to SARS-CoV-2 vaccination compared with healthy controls, according to research presented at the International Liver Congress.

LONDON — Exposure to proton pump inhibitors correlated with an increased risk for severe infection and cirrhosis decompensation among a subset of patients with cirrhosis, according to research presented at the International Liver Congress.

LONDON — Patients with nonalcoholic fatty liver disease had worse health-related quality of life, regardless of fibrosis stage, compared with the general population, according to research presented at the International Liver Congress.

LONDON — The Gender-Equity Model for Liver Allocation and its sodium-corrected variant were better predictors of mortality or delisting in patients awaiting liver transplantation and may correct gender disparities, according to research.

LONDON — Therapy combining small interfering RNA, capsid assembly modulator and nucleotide analogue reduced HBsAg levels over 24 weeks compared with standard therapy, according to a presenter at the International Liver Congress.